YourRhythmics B.V., founded at the end of 2016 by Brightlands Life Science Ventures and Maastricht University, has shown on the basis of clinical studies that subtle patterns in the electrocardiogram (ECG) show the structural damage to the muscle tissue that causes AF. The more complex these patterns are, the heavier the intervention has to be to reduce or eliminate AF. Based on the above results, the company has developed software in close collaboration with the School for Cardiovascular Disease (CARIM Institute) of Maastricht University that uses artificial intelligence to recognize these patterns in the heart signal. The company’s vision is to enable cardiologists to provide early diagnosis and personalized treatment of AF. This raises the success rate of successful treatment of atrial fibrillation well above 70%, a highly desirable solution according to leading cardiologists.
Medlodi B.V., specialized in financing and business development for early-stage MedTech companies, has made this financing possible with business angels. Being responsible for YourRhythmics management, Medlodi ensures the acceleration of business potential and medical certification across its most important markets.
For further information, please contact: